6533b85ffe1ef96bd12c1a52
RESEARCH PRODUCT
P-342 Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer
Markus MoehlerDaniel Virgil Thomas CatenacciLiang ShenM. Koshiji RosalesY. KangH.c. ChungHarry H. Yoonsubject
Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentMargetuximabAnti pd 1CancerHematologyGastroesophageal Junctionmedicine.diseaseFirst line therapyOncologyInternal medicinemedicinebusinessyear | journal | country | edition | language |
---|---|---|---|---|
2020-07-01 | Annals of Oncology |